KINAXO Launches KinAffinity Services

KINAXO Biotechnologies has added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitor’s selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins, said the company.

The company claims that KinAffinity provides critical information to select the right lead compound for clinical development. KinAffinity combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry.

KinAffinity is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.